Switch View
© BusinessWire
04.11.2025
ISIN: US2560861096
DocGo Inc
DCGO
LISTED
NASDAQ
DocGo Announces Upcoming Launch of Longitudinal Care Services for Major California Health Plan
News Preview
DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced plans to launch Longitudinal Care Services in partnership with a California-based insurance provider. Leveraging the Company’s primary care capabilities, this program will provide prevent...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US8723811084
TELA Bio Inc
TELA
LISTED
NASDAQ
TELA Bio to Announce Third Quarter 2025 Financial Results
News Preview
MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US04280A1007
Arrowhead Pharmaceuticals Inc
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
American Heart Association (AHA) Scientific Sessions 2025 – November 7-10, 2025
Title: Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Zodasiran in Adoles...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
04.11.2025
ISIN: US4131971040
Harmony Biosciences Holdings Inc
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ever increase in average number of patients of approximately 500 for the quarter, accelerating the trajectory toward blockbuster status for WAKIX in n...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
ISIN: US67080T1088
Nuvectis Pharma Inc
NVCT
LISTED
NASDAQ
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US4277461020
Heron Therapeutics Inc
HRTX
LISTED
NASDAQ
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
News Preview
CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US30068X1037
Exagen Inc
XGN
LISTED
NASDAQ
Exagen Inc. Reports Strong Q3 2025 Results
News Preview
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US0223071020
Alumis, Inc.
ALMS
LISTED
NASDAQ
Alumis to Participate in Upcoming November Investor Conferences
News Preview
Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US12674W1099
Cabaletta Bio Inc
CABA
LISTED
NASDAQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
News Preview
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US03969K1088
Arcutis Biotherapeutics Inc
ARQT
LISTED
NASDAQ
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
News Preview
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US0396971071
Ardelyx Inc
ARDX
LISTED
NASDAQ
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
News Preview
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbu...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US29664W1053
Esperion Therapeutics Inc
ESPR
LISTED
NASDAQ
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
News Preview
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
04.11.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Summit Therapeutics to Present at Upcoming Investor Conferences
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences:
UBS Glo...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation to Present at Upcoming Investor Conferences
News Preview
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences.
Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Co...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US00653Q1022
Adapthealth Corp
AHCO
LISTED
NASDAQ
AdaptHealth Corp. Announces Third Quarter 2025 Results
News Preview
AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the third quarter ended September 30, 2025.
Third Quarter Business Highlights
Signed anot...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December.
Jefferies London Global Healthcare Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US68752M1080
Orthofix Medical Inc
OFIX
LISTED
NASDAQ
Orthofix Reports Third Quarter 2025 Financial Results
News Preview
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this re...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US30063P1057
Exact Sciences Corp
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in November Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jefferies London Healthcare Conference, London
Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US98978V1035
Zoetis Inc
ZTS
LISTED
NYSE
Zoetis Announces Third Quarter 2025 Results
News Preview
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.
The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 20...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface ant...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
News Preview
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“I am proud of Pfizer’s leadership as the first in our industry to reach an agreemen...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerl...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US09075A1088
Bioventus Inc
BVS
LISTED
NASDAQ
Bioventus Reports Third Quarter Financial Results
News Preview
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
News Preview
WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no FDA-approved therapies, today announced that it will report it...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Participate in November Investor Conferences
News Preview
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier, Inc. Reports Fiscal-Year 2026 First-Quarter Financial Results
News Preview
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2026 first quarter ended September 30, 2025.
Fiscal-year 2026 first quarter total net revenue of $240.0 million decreased 3% from the prior-year period. Net income from continuing operations of $15.3 mill...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US45685K1025
InfuSystem Holdings Inc
INFU
LISTED
XASE
InfuSystem Reports Third Quarter 2025 Financial Results
News Preview
InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2025.
2025 Third Quarter Overview:
Net rev...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US8688731004
Surmodics Inc
SRDX
LISTED
NASDAQ
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
News Preview
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US67576A1007
Ocular Therapeutix Inc
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
Prelude Therapeutics Announces Strategic Business Update
News Preview
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US64131A1051
Neuronetics Inc
STIM
LISTED
NASDAQ
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
News Preview
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
News Preview
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end
21.1 month median OS and 7.0 month median PFS reported from single-arm...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US9418481035
Waters Corp
WAT
LISTED
NYSE
Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
News Preview
Highlights
Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency
Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% g...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US9418481035
Waters Corp
WAT
LISTED
NYSE
Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
News Preview
Highlights
Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency
Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% g...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US83601L1026
Sotera Health Co
SHC
LISTED
NASDAQ
Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
News Preview
Sotera Health Q3 2025 Earnings Release...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US76243J1051
Rhythm Pharmaceuticals Inc
RYTM
LISTED
NASDAQ
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
News Preview
-- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity --...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US07373V1052
Beam Therapeutics Inc
BEAM
LISTED
NASDAQ
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
News Preview
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US5015751044
Kymera Therapeutics Inc
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
News Preview
Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US03152W1099
Amicus Therapeutics Inc
FOLD
LISTED
NASDAQ
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
News Preview
Q3 2025 Total Revenue of $169M, up 17% at CER...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US95075A1079
Werewolf Therapeutics Inc
HOWL
LISTED
NASDAQ
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US5588681057
Madrigal Pharmaceuticals Inc
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
News Preview
CONSHOHOCKEN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: CH0329023102
AC Immune SA
ACIU
LISTED
NASDAQ
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US45779A8466
InspireMD, Inc.
NSPR
LISTED
NASDAQ
InspireMD Reports Third Quarter 2025 Financial Results
News Preview
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: CA05156V1022
Aurinia Pharmaceuticals Inc
AUPH
LISTED
NASDAQ
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
News Preview
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress.
Financial Results
Total Revenue: For the three and nine months ended September 30, 2025, total revenue was $73.5 million and $205.9 million, up 8% and 17%, resp...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US8064071025
Henry Schein Inc
HSIC
LISTED
NASDAQ
Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance
News Preview
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 27, 2025.
“We are pleased with our financial results for the third quarter, with sales growth accelerating in each of our reportable segme...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Montega AG: Medios AG | Rating: Kaufen
News Preview
Original-Research: Medios AG - von Montega AG
04.11.2025 / 11:41 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss......
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US50127T1097
Kura Oncology Inc
KURA
LISTED
NASDAQ
Kura Oncology Reports Third Quarter 2025 Financial Results
News Preview
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: CA72706K1012
Planet 13 Holdings Inc.
PLTH
LISTED
CSE
Planet 13 Announces Release Date of Third Quarter 2025 Financial Results
News Preview
LAS VEGAS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, announced today that it plans to release its financial results for the third quarter ended September 30th, 2025, on November 12th, 2025, aftermarket....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US2210061097
CorVel Corp
CRVL
LISTED
NASDAQ
CorVel Announces Revenues and Earnings
News Preview
FORT WORTH, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended September 30, 2025. Revenues for the quarter were $240 million, an increase from $224 million in the September quarter of 2024. Earnings per share for the quarter were $0.54, compared to $0.45 in the same quarter of t...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US7504911022
RadNet Inc
RDNT
LISTED
NASDAQ
RadNet Announces the Agenda for its November 11, 2025 Investor Day
News Preview
RadNet Announces the Agenda for its November 11, 2025 Investor Day...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: JP3431300007
Nxera Pharma Co Ltd
45650
LISTED
XJPX
Nxera Pharma to Host R&D Day 2025
News Preview
Tokyo, Japan and Cambridge, UK, 4 November 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces that it will hold an R&D Day on 18 November 2025 at 17:00 JST....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an a...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an a...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2025
ISIN: US9174881089
Utah Medical Products Inc
UTMD
LISTED
NASDAQ
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
News Preview
SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors. Mr. Timken, who served as UTMD's outside legal counsel for over twenty years prior to his retirement in 2025, graduated with a J.D. degree from the Un...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
ISIN: CA24463V1013
Defence Therapeutics Inc.
DTC
LISTED
CSE
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
News Preview
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from it...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2025
ISIN: CA00143Y1034
AI-ML Innovations Inc.
AIML
LISTED
CSE
AIML Subsidiary NeuralCloud Solutions Engages Lonacas Consultants to Lead Regulatory Submission for CardioYield(TM) in Jamaica
News Preview
Collaboration Advances Local Regulatory Pathway for AI-Enabled ECG Diagnostics to Address the Growing Cardiovascular Disease Burden in Jamaica TORONTO, ON / ACCESS Newswire / November 4, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that its wholly owned subsidia...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
News Preview
COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
